FDA Approves Dalteparin Sodium for VTE in Pediatric Patients
May 17
2019
The Food and Drug Administration approved dalteparin sodium (FRAGMIN, Pfizer, Inc.) to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients 1 month of age and older.